Ask VialBase
Research

A Study of Retatrutide in Participants With Obesity and Chronic Low Back Pain — VialBase Research

Trial Summary

Phase 3 trial investigating retatrutide for obesity-associated chronic low back pain (CLBP). Chronic low back pain is the leading cause of disability worldwide, and obesity significantly worsens spinal loading, disc degeneration, and systemic inflammation. This trial tests whether aggressive pharmacological weight loss can provide clinically meaningful pain relief.

Design

  • Type: Randomized, double-blind, placebo-controlled, multicenter
  • Population: Adults with BMI 30+ and chronic low back pain (3+ months, moderate-severe)
  • Arms: Retatrutide vs. placebo
  • Duration: 52+ weeks
  • Key measures: Numeric Rating Scale (NRS) pain intensity, Oswestry Disability Index, body weight, functional measures, analgesic use

Key Outcomes

Trial is recruiting; no results available yet.

Significance for Peptide Research

This is a novel and ambitious indication for a peptide therapeutic. If retatrutide reduces chronic low back pain through weight loss and anti-inflammatory effects, it could disrupt the massive pain management market. The combination of mechanical unloading (weight loss) and potential anti-inflammatory effects (GLP-1/glucagon signaling) makes this a compelling biological hypothesis. Connects to the obesity-driven musculoskeletal disease evidence base and may reduce opioid dependence in this population.

See Also